Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

SYN-007, an Orally Administered Beta-Lactamase Enzyme, Protects the Gut Microbiome from Oral Amoxicillin/Clavulanate without Adversely Affecting Antibiotic Systemic Absorption in Dogs.

Connelly S, Fanelli B, Hasan NA, Colwell RR, Kaleko M.

Microorganisms. 2020 Jan 22;8(2). pii: E152. doi: 10.3390/microorganisms8020152.

2.

Low dose oral beta-lactamase protects the gut microbiome from oral beta-lactam-mediated damage in dogs.

Connelly S, Fanelli B, Hasan NA, Colwell RR, Kaleko M.

AIMS Public Health. 2019 Nov 12;6(4):477-487. doi: 10.3934/publichealth.2019.4.477. eCollection 2019.

3.

Oral Beta-Lactamase Protects the Canine Gut Microbiome from Oral Amoxicillin-Mediated Damage.

Connelly S, Fanelli B, Hasan NA, Colwell RR, Kaleko M.

Microorganisms. 2019 May 27;7(5). pii: E150. doi: 10.3390/microorganisms7050150.

4.

Oral Metallo-Beta-Lactamase Protects the Gut Microbiome From Carbapenem-Mediated Damage and Reduces Propagation of Antibiotic Resistance in Pigs.

Connelly S, Fanelli B, Hasan NA, Colwell RR, Kaleko M.

Front Microbiol. 2019 Feb 5;10:101. doi: 10.3389/fmicb.2019.00101. eCollection 2019.

5.

Identification, Characterization, and Formulation of a Novel Carbapenemase Intended to Prevent Antibiotic-Mediated Gut Dysbiosis.

Connelly S, Parsley T, Ge H, Kaleko M.

Microorganisms. 2019 Jan 16;7(1). pii: E22. doi: 10.3390/microorganisms7010022.

6.

Distinct consequences of amoxicillin and ertapenem exposure in the porcine gut microbiome.

Connelly S, Subramanian P, Hasan NA, Colwell RR, Kaleko M.

Anaerobe. 2018 Oct;53:82-93. doi: 10.1016/j.anaerobe.2018.04.012. Epub 2018 Apr 22.

PMID:
29689301
7.

SYN-004 (ribaxamase), an oral beta-lactamase, mitigates antibiotic-mediated dysbiosis in a porcine gut microbiome model.

Connelly S, Bristol JA, Hubert S, Subramanian P, Hasan NA, Colwell RR, Kaleko M.

J Appl Microbiol. 2017 Jul;123(1):66-79. doi: 10.1111/jam.13432. Epub 2017 May 23.

PMID:
28245091
8.

Prior exposure to Bordetella species as an exclusion criterion in the baboon model of pertussis.

Nguyen AW, Wagner EK, Posada L, Liu X, Connelly S, Papin JF, Wolf RF, Kaleko M, Maynard JA.

J Vet Med Sci. 2017 Jan 20;79(1):60-64. doi: 10.1292/jvms.16-0427. Epub 2016 Sep 26.

9.

Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection.

Kaleko M, Bristol JA, Hubert S, Parsley T, Widmer G, Tzipori S, Subramanian P, Hasan N, Koski P, Kokai-Kun J, Sliman J, Jones A, Connelly S.

Anaerobe. 2016 Oct;41:58-67. doi: 10.1016/j.anaerobe.2016.05.015. Epub 2016 Jun 2.

10.

A cocktail of humanized anti-pertussis toxin antibodies limits disease in murine and baboon models of whooping cough.

Nguyen AW, Wagner EK, Laber JR, Goodfield LL, Smallridge WE, Harvill ET, Papin JF, Wolf RF, Padlan EA, Bristol A, Kaleko M, Maynard JA.

Sci Transl Med. 2015 Dec 2;7(316):316ra195. doi: 10.1126/scitranslmed.aad0966.

11.

Complete sequence and organization of the human adenovirus serotype 46 genome.

Reddy PS, Ganesh S, Knowles NJ, Kaleko M, Connelly S, Bristol A.

Virus Res. 2006 Mar;116(1-2):119-28. Epub 2005 Oct 20.

PMID:
16242804
12.

Increased expression of VEGF in retinal pigmented epithelial cells is not sufficient to cause choroidal neovascularization.

Oshima Y, Oshima S, Nambu H, Kachi S, Hackett SF, Melia M, Kaleko M, Connelly S, Esumi N, Zack DJ, Campochiaro PA.

J Cell Physiol. 2004 Dec;201(3):393-400.

PMID:
15389527
13.

A synthetic Rev-independent bovine immunodeficiency virus-based packaging construct.

Molina RP, Ye HQ, Brady J, Zhang J, Zimmerman H, Kaleko M, Luo T.

Hum Gene Ther. 2004 Sep;15(9):865-77.

PMID:
15353041
14.

Angiopoietin-2 enhances retinal vessel sensitivity to vascular endothelial growth factor.

Oshima Y, Deering T, Oshima S, Nambu H, Reddy PS, Kaleko M, Connelly S, Hackett SF, Campochiaro PA.

J Cell Physiol. 2004 Jun;199(3):412-7.

PMID:
15095288
15.

Intraocular gutless adenoviral-vectored VEGF stimulates anterior segment but not retinal neovascularization.

Oshima Y, Takahashi K, Oshima S, Saishin Y, Saishin Y, Silva RL, Liang X, Reddy PS, Ganesh S, Brann T, Liau G, Kaleko M, Connelly S, Campochiaro PA.

J Cell Physiol. 2004 Jun;199(3):399-411.

PMID:
15095287
16.

Potentiation of oncolytic adenoviral vector efficacy with gutless vectors encoding GMCSF or TRAIL.

Burroughs KD, Kayda DB, Sakhuja K, Hudson Y, Jakubczak J, Bristol JA, Ennist D, Hallenbeck P, Kaleko M, Connelly S.

Cancer Gene Ther. 2004 Feb;11(2):92-102.

PMID:
14730331
17.

Receptor interactions involved in adenoviral-mediated gene delivery after systemic administration in non-human primates.

Smith TA, Idamakanti N, Marshall-Neff J, Rollence ML, Wright P, Kaloss M, King L, Mech C, Dinges L, Iverson WO, Sherer AD, Markovits JE, Lyons RM, Kaleko M, Stevenson SC.

Hum Gene Ther. 2003 Nov 20;14(17):1595-604.

PMID:
14633402
18.

Synthesis of adenoviral targeting molecules by intein-mediated protein ligation.

Nyanguile O, Dancik C, Blakemore J, Mulgrew K, Kaleko M, Stevenson SC.

Gene Ther. 2003 Aug;10(16):1362-9.

PMID:
12883533
19.

Development of adenovirus serotype 35 as a gene transfer vector.

Seshidhar Reddy P, Ganesh S, Limbach MP, Brann T, Pinkstaff A, Kaloss M, Kaleko M, Connelly S.

Virology. 2003 Jul 5;311(2):384-93.

20.

Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice.

Smith TA, Idamakanti N, Rollence ML, Marshall-Neff J, Kim J, Mulgrew K, Nemerow GR, Kaleko M, Stevenson SC.

Hum Gene Ther. 2003 May 20;14(8):777-87.

PMID:
12804140
21.

In vivo ligand-inducible regulation of gene expression in a gutless adenoviral vector system.

Zerby D, Sakhuja K, Reddy PS, Zimmerman H, Kayda D, Ganesh S, Pattison S, Brann T, Kadan MJ, Kaleko M, Connelly S.

Hum Gene Ther. 2003 May 20;14(8):749-61.

PMID:
12804138
22.

Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment.

Takahashi K, Saishin Y, Saishin Y, Silva RL, Oshima Y, Oshima S, Melia M, Paszkiet B, Zerby D, Kadan MJ, Liau G, Kaleko M, Connelly S, Luo T, Campochiaro PA.

FASEB J. 2003 May;17(8):896-8. Epub 2003 Mar 28.

PMID:
12670875
23.

Optimization of the generation and propagation of gutless adenoviral vectors.

Sakhuja K, Reddy PS, Ganesh S, Cantaniag F, Pattison S, Limbach P, Kayda DB, Kadan MJ, Kaleko M, Connelly S.

Hum Gene Ther. 2003 Feb 10;14(3):243-54.

PMID:
12639304
24.

Mapping of the bovine immunodeficiency virus packaging signal and RRE and incorporation into a minimal gene transfer vector.

Molina RP, Matukonis M, Paszkiet B, Zhang J, Kaleko M, Luo T.

Virology. 2002 Dec 5;304(1):10-23.

25.

Evaluation of the duration of human factor VIII expression in nonhuman primates after systemic delivery of an adenoviral vector.

Andrews JL, Shirley PS, Iverson WO, Sherer AD, Markovits JE, King L, Lyons RM, Kaleko M, Connelly S.

Hum Gene Ther. 2002 Jul 20;13(11):1331-6.

PMID:
12162815
26.

Sustained transduction of ocular cells with a bovine immunodeficiency viral vector.

Takahashi K, Luo T, Saishin Y, Saishin Y, Sung J, Hackett S, Brazzell RK, Kaleko M, Campochiaro PA.

Hum Gene Ther. 2002 Jul 20;13(11):1305-16.

PMID:
12162813
27.

Development of second- and third-generation bovine immunodeficiency virus-based gene transfer systems.

Matukonis M, Li M, Molina RP, Paszkiet B, Kaleko M, Luo T.

Hum Gene Ther. 2002 Jul 20;13(11):1293-303.

PMID:
12162812
28.

In vivo hepatic adenoviral gene delivery occurs independently of the coxsackievirus-adenovirus receptor.

Smith T, Idamakanti N, Kylefjord H, Rollence M, King L, Kaloss M, Kaleko M, Stevenson SC.

Mol Ther. 2002 Jun;5(6):770-9.

29.

Uncoupling of protein-3 induces an uncontrolled uncoupling of mitochondria after expression in muscle derived L6 cells.

Guerini D, Prati E, Desai U, Nick HP, Flammer R, GrĂ¼ninger S, Cumin F, Kaleko M, Connelly S, Chiesi M.

Eur J Biochem. 2002 Mar;269(5):1373-81.

30.

Targeting adenoviral vectors by using the extracellular domain of the coxsackie-adenovirus receptor: improved potency via trimerization.

Kim J, Smith T, Idamakanti N, Mulgrew K, Kaloss M, Kylefjord H, Ryan PC, Kaleko M, Stevenson SC.

J Virol. 2002 Feb;76(4):1892-903.

31.

Sustained human factor VIII expression in hemophilia A mice following systemic delivery of a gutless adenoviral vector.

Reddy PS, Sakhuja K, Ganesh S, Yang L, Kayda D, Brann T, Pattison S, Golightly D, Idamakanti N, Pinkstaff A, Kaloss M, Barjot C, Chamberlain JS, Kaleko M, Connelly S.

Mol Ther. 2002 Jan;5(1):63-73.

32.

Phenotypic correction of diabetic mice by adenovirus-mediated glucokinase expression.

Desai UJ, Slosberg ED, Boettcher BR, Caplan SL, Fanelli B, Stephan Z, Gunther VJ, Kaleko M, Connelly S.

Diabetes. 2001 Oct;50(10):2287-95.

33.

Adenovirus-mediated factor VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII protein infusion.

Bristol JA, Gallo-Penn A, Andrews J, Idamakanti N, Kaleko M, Connelly S.

Hum Gene Ther. 2001 Sep 1;12(13):1651-61.

PMID:
11535168
34.

Treatment of type 2 diabetes by adenoviral-mediated overexpression of the glucokinase regulatory protein.

Slosberg ED, Desai UJ, Fanelli B, St Denny I, Connelly S, Kaleko M, Boettcher BR, Caplan SL.

Diabetes. 2001 Aug;50(8):1813-20.

35.

Generation and characterization of E1/E2a/E3/E4-deficient adenoviral vectors encoding human factor VIII.

Andrews JL, Kadan MJ, Gorziglia MI, Kaleko M, Connelly S.

Mol Ther. 2001 Mar;3(3):329-36.

36.

Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs.

Gallo-Penn AM, Shirley PS, Andrews JL, Tinlin S, Webster S, Cameron C, Hough C, Notley C, Lillicrap D, Kaleko M, Connelly S.

Blood. 2001 Jan 1;97(1):107-13.

PMID:
11133749
37.

In vivo dose threshold effect of adenovirus-mediated factor VIII gene therapy in hemophiliac mice.

Bristol JA, Shirley P, Idamakanti N, Kaleko M, Connelly S.

Mol Ther. 2000 Sep;2(3):223-32.

38.

Adenoviral vector-mediated expression of physiologic levels of human factor VIII in nonhuman primates.

Brann T, Kayda D, Lyons RM, Shirley P, Roy S, Kaleko M, Smith T.

Hum Gene Ther. 1999 Dec 10;10(18):2999-3011.

PMID:
10609660
39.

In vivo evaluation of a novel epitope-tagged human factor VIII-encoding adenoviral vector.

Roy S, Shirley PS, Connelly S, Andrews JL, Kayda DB, Gardner JM, Kaleko M.

Haemophilia. 1999 Sep;5(5):340-8.

PMID:
10583516
40.

In vivo evaluation of an adenoviral vector encoding canine factor VIII: high-level, sustained expression in hemophiliac mice.

Gallo-Penn AM, Shirley PS, Andrews JL, Kayda DB, Pinkstaff AM, Kaloss M, Tinlin S, Cameron C, Notley C, Hough C, Lillicrap D, Kaleko M, Connelly S.

Hum Gene Ther. 1999 Jul 20;10(11):1791-802.

PMID:
10446919
41.
42.

Generation of an adenovirus vector lacking E1, e2a, E3, and all of E4 except open reading frame 3.

Gorziglia MI, Lapcevich C, Roy S, Kang Q, Kadan M, Wu V, Pechan P, Kaleko M.

J Virol. 1999 Jul;73(7):6048-55.

43.

Evaluation of an adenoviral vector encoding full-length human factor VIII in hemophiliac mice.

Connelly S, Andrews JL, Gallo-Penn AM, Tagliavacca L, Kaufman RJ, Kaleko M.

Thromb Haemost. 1999 Feb;81(2):234-9.

PMID:
10063998
44.

Haemophilia A gene therapy.

Connelly S, Kaleko M.

Haemophilia. 1998 Jul;4(4):380-8. Review.

PMID:
9873758
45.

Circumvention of immunity to the adenovirus major coat protein hexon.

Roy S, Shirley PS, McClelland A, Kaleko M.

J Virol. 1998 Aug;72(8):6875-9.

46.

Multivalent cations and ligand affinity of the type 1 insulin-like growth factor receptor on P2A2-LISN muscle cells.

McCusker RH, Kaleko M, Sackett RL.

J Cell Physiol. 1998 Aug;176(2):392-401.

PMID:
9648927
47.

An improved method for generating retroviral producer clones for vectors lacking a selectable marker gene.

Persons DA, Mehaffey MG, Kaleko M, Nienhuis AW, Vanin EF.

Blood Cells Mol Dis. 1998 Jun;24(2):167-82.

PMID:
9642098
48.

Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy.

Connelly S, Andrews JL, Gallo AM, Kayda DB, Qian J, Hoyer L, Kadan MJ, Gorziglia MI, Trapnell BC, McClelland A, Kaleko M.

Blood. 1998 May 1;91(9):3273-81.

PMID:
9558383
49.

Gene therapy for hemophilia A.

Connelly S, Kaleko M.

Thromb Haemost. 1997 Jul;78(1):31-6. Review.

PMID:
9198123
50.

Complete short-term correction of canine hemophilia A by in vivo gene therapy.

Connelly S, Mount J, Mauser A, Gardner JM, Kaleko M, McClelland A, Lothrop CD Jr.

Blood. 1996 Nov 15;88(10):3846-53.

PMID:
8916949

Supplemental Content

Loading ...
Support Center